Focused On-demand Library for Glycosylphosphatidylinositol-anchored high density lipoprotein-binding protein 1

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.

We employ our advanced, specialised process to create targeted libraries for enzymes.

Fig. 1. The sreening workflow of Receptor.AI

It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.

Key features that set our library apart include:

The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

Q8IV16

UPID:

HDBP1_HUMAN

Alternative names:

High density lipoprotein-binding protein 1

Alternative UPACC:

Q8IV16; Q6P3T2; Q86W15

Background:

Glycosylphosphatidylinositol-anchored high density lipoprotein-binding protein 1, also known as High density lipoprotein-binding protein 1, plays a pivotal role in lipid metabolism. It facilitates the transport and anchoring of lipoprotein lipase (LPL) on endothelial cells, crucial for lipolytic processing of chylomicrons, triglyceride metabolism, and overall lipid homeostasis. This protein also interacts with chylomicrons, phospholipid particles containing APOA5, and high-density lipoprotein (HDL), influencing lipid uptake from HDL.

Therapeutic significance:

Hyperlipoproteinemia 1D, a disorder marked by hyperlipoproteinemia, decreased plasma LPL levels, high plasma triglyceride levels, and refractory fasting chylomicronemia, is associated with variants affecting this protein. Understanding the role of Glycosylphosphatidylinositol-anchored high density lipoprotein-binding protein 1 could open doors to potential therapeutic strategies for lipid metabolism disorders.